Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors

    January 2001 in “ Science ”
    Stephen T. Davis, Bill Benson, H. Neal Bramson, Dennis E. Chapman, Scott H. Dickerson, Karen M. Dold, Derek J. Eberwein, Mark P. Edelstein, Stephen V. Frye, Robert T. Gampe, Robert J. Griffin, Philip A. Harris, Anne M. Hassell, William D. Holmes, Robert N. Hunter, Victoria B. Knick, Karen Lackey, Brett Lovejoy, Michael J. Luzzio, Doris M. Murray, Patricia A. Parker, Warren J. Rocque, Lisa M. Shewchuk, James M. Veal, Duncan Walker, Lee F. Kuyper
    Image of study
    TLDR Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
    The study by Stephen T. Davis et al. from 2001 explored the use of CDK2 inhibitors to prevent chemotherapy-induced alopecia (CIA) in a neonatal rat model. The researchers found that topical application of these inhibitors reduced hair loss in 33 to 50% of the rats. The study included nine experiments for the etoposide model and three for the cyclophosphamide-doxorubicin model, demonstrating that the compound arrested the cell cycle and protected cells from chemotherapy toxicity. Despite initial positive results suggesting that clinical trials might be warranted, the document notes that the article was retracted on December 20, 2002, due to the inability to reproduce the biological activity of the compound in subsequent experiments.
    Discuss this study in the Community →

    Cited in this study

    3 / 3 results